Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Bishop Hans Edgar
Relationship:   Director
City:   Seattle
State:   WA
   
Insider Summary:
  
   
Companies Owned :   7    
Direct Shares   10,734,769    

Indirect Shares

   0      
Direct Value   $16,077,755    

Indirect Value

   $0      
Total Shares   10,734,769      
Total Value   $16,077,755      


Dendreon Corp $0 Avanir Pharmaceuticals $0 Agilent Technologies Inc $3,848,302 Sana Biotechnology, Inc. $0 Lyell Immunopharma, Inc. $12,229,453 Dendreon Corp $0 Avanir Pharmaceuticals $0 Agilent Technologies Inc $3,848,302 Sana Biotechnology, Inc. $0 Lyell Immunopharma, Inc. $12,229,453
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    0   
    0    

     Stock price went up :
    0   
    0    
     Stock price went down :
    0   
    0    
   
     Gain/Loss Ratio :
   0.0   
   0.0   
     Percentage Gain/Loss :
     0.0%
   0.0%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Dendreon Corp DNDN Chief Operating Officer 2011-07-29 151,189 2010-01-29 0    Premium*  
            Avanir Pharmaceuticals AVNR Director 2014-02-12 93,350 2013-02-14 0    Premium*  
            Juno Therapeutics, Inc. JUNO CEO & President, Direc... 2018-03-05 0 0    Premium*  
            Agilent Technologies Inc A Director 2024-03-15 24,976 2017-07-18 0    Premium*  
            Celgene Corp CELG 2019-11-20 0 2019-11-20 0    Premium*  
            Sana Biotechnology, Inc. SANA 2024-04-05 5,779,640 0    Premium*  
            Lyell Immunopharma, Inc. LYEL Director 2022-09-08 4,685,614 2021-06-21 0    Premium*  
* Premium Members only  

Records found :    62         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 1 of 3
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2010-01-29 4 A $0.00 $0 D/D 110,000 110,000 0 -
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2010-12-07 4 A $0.00 $0 D/D 27,000 137,000 0 -
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2011-01-20 4 A $0.00 $0 D/D 28,051 165,051 0 -
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2011-02-10 4 D $35.01 $323,107 D/D (9,229) 155,822 0 -
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2011-04-29 4 D $42.27 $98,998 D/D (2,342) 153,480 0 -
DNDN Dendreon Corp Chief Operating Officer   •       –      –    2011-07-29 4 D $37.65 $86,256 D/D (2,291) 151,189 0 -
AVNR Avanir Pharmaceuticals Director   –       •      –    2013-02-14 4 A $0.00 $0 D/D 19,450 64,450 0 -
AVNR Avanir Pharmaceuticals Director   –       •      –    2014-02-12 4 A $0.00 $0 D/D 28,900 93,350 0 -
JUNO Juno Therapeutics, Inc. See RemarksOfficer   •       •      –    2014-12-18 3 IO $0.00 $0 D/D 0 2,724,859 -
JUNO Juno Therapeutics, Inc. CEO and President   •       •      –    2015-12-15 4 OE $6.36 $343,440 D/D 54,000 2,778,859 0 -
JUNO Juno Therapeutics, Inc. CEO and President   •       •      –    2015-12-15 4 AS $44.77 $4,183,411 D/D (91,500) 2,687,359 0 -
JUNO Juno Therapeutics, Inc. See Remarks   •       •      –    2016-02-29 4 OE $6.36 $343,440 D/D 54,000 2,741,359 0 -
JUNO Juno Therapeutics, Inc. See Remarks   •       •      –    2016-02-29 4 AS $35.27 $3,205,005 D/D (90,750) 2,650,609 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-06-09 4 OE $6.36 $343,440 D/D 54,000 2,704,609 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-06-09 4 AS $45.80 $4,212,344 D/D (90,750) 2,613,859 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-06-30 4/A AS $38.41 $4,431,116 D/D (115,250) 2,542,609 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-06-30 4 D $38.41 $4,431,116 D/D (115,250) 2,542,609 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-06-30 4 OE $6.36 $279,840 D/D 44,000 2,657,859 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-08-31 4 OE $6.36 $115,580 D/D 18,173 2,560,782 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-08-31 4 AS $30.06 $1,282,554 D/D (42,673) 2,518,109 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-09-08 4 OE $6.36 $146,547 D/D 23,042 2,541,151 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-09-08 4 AS $30.06 $692,578 D/D (23,042) 2,518,109 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-09-19 4 OE $6.36 $2,722 D/D 428 2,518,537 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-09-19 4 AS $30.00 $12,840 D/D (428) 2,518,109 0 -
JUNO Juno Therapeutics, Inc. CEO & President   •       •      –    2016-09-20 4 AS $30.00 $189,003 D/D (6,300) 2,518,109 0 -
  62  Records found
  1  2   3      
  Page 1 of 3  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us